- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05157581
Extracorporeal Photopheresis in Sezary Syndrome (ECP)
Open Label, Single-cohort, and Single-center Phase II Study Evaluating Tumor-specific Immunity After Extracorporeal Photopheresis in Patients With Sézary Syndrome at Single-cell Resolution
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cutaneous T-cell lymphoma (CTCL) is a group of skin lymphomas in which malignant lymphocytes infiltrate the skin and, in the later stages, spread to the lymph nodes and blood (leukemia). In the early stages, CTCL generally has a slow course, but in advanced diseases, such as Sezary syndrome (the leukemic form of the disease), there is rapid deterioration. Sezary syndrome is an end-stage variant of CTCL with a mean survival of 1.5 years despite aggressive therapies. Treatment options for the advanced disease are severely limited.
In this study, informed consent will be offered to patients who are candidates for standard of care ECP and have a diagnosis of Sezary Syndrome. Participating patients will undergo ECP twice weekly for 4 weeks then twice monthly for 5 more months (month 6 of therapy). Research blood samples to assess immune responses will be obtained from a blood draw at baseline (before starting ECP), one day after first ECP, and at months 1, 3, and 6. Standard of care assessments to determine the objective response will include measurement of skin tumor burden (mSWAT), blood tumor burden (flow cytometry) and CT scan at baseline and only repeated at month 3 and 6 if lymph node or visceral (organ) involvement identified at baseline.
The investigators propose to establish changes in the tumor microenvironment after ECP, compare transcriptomic differences in malignant lymphocytes, monocytes, DC, and CD8 effectors before and after ECP to test the hypothesis that anti-tumor immune responses can be induced by ECP. We will employ a highly innovative technology such as single-cell RNA sequencing (scRNAseq) coupled with TCR sequencing to characterize ECP-related change in malignant cells utilizing a custom gene set and validate the single-cell protein data by antibody-oligo conjugates. To better understand the relevance of biomarker changes to disease progression, the observed ECP-related changes in tumor microenvironment will be correlated with clinical outcomes.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Nicolena Verardi, PA-C
- Phone Number: 412-864-3682
- Email: verardin3@upmc.edu
Study Contact Backup
- Name: Charity Ruhl, LPN
- Phone Number: 4126472013
- Email: ruhlcl@upmc.edu
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- University of Pittsburgh Medical Center
-
Contact:
- Nicolena Verardi, PA-C
- Phone Number: 412-864-3682
- Email: verardin3@upmc.edu
-
Principal Investigator:
- Oleg E Akilov, MD, PhD
-
Contact:
- Charity Ruhl, LPN
- Phone Number: 412-647-2013
- Email: ruhlcl@upmc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient with an established diagnosis of Sezary syndrome (stage IVA1)
- The patient must have a minimum wash-out period of 3 weeks between the last dose of prior systemic therapy
- Patients should have recovered from all adverse events related to prior therapy to ≤ grade 1
- Signed informed consent form prior to any protocol-specific procedures.
Exclusion Criteria:
- Visceral metastasis of lymphoma
- Concomitant administration of radiotherapy or systemic anti-cancer therapy including but not restricted to: chemotherapy, biological agents, or immunotherapy
- Patients with known NCI CTCAE grade 3 or higher active systemic or cutaneous viral, bacterial, or fungal infection.
- Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment and/or comply with study protocol.
- Patients with dementia or altered mental status that would preclude understanding and rendering of informed consent document.
- Patients with known allergy to methoxsalen or heparin -
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Sezary Syndrome
15 subjects with Sezary Syndrome will comprise the single arm of this study
|
Extracorporeal photopheresis is a process that exposes a collection of white blood cells and plasma to a light sensitizing agent, methoxsalen, and returns that compartment to the body.
Other Names:
Methoxsalen is a light-sensitizing sterile compound added to the collected white blood cells and plasma during ECP.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in tumor-specific immunity
Time Frame: Up to 3 months post baseline
|
Evaluate immune responses post ECP using innovative technology such as single-cell RNA sequencing (scRNAseq) coupled with TCR sequencing to characterize ECP-related change in malignant cells
|
Up to 3 months post baseline
|
Change from baseline in tumor-specific immunity
Time Frame: Up to 6 months post baseline
|
Evaluate immune responses post ECP using innovative technology such as single-cell RNA sequencing (scRNAseq) coupled with TCR sequencing to characterize ECP-related change in malignant cells
|
Up to 6 months post baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in the objective response rate for ECP therapy
Time Frame: Up to 3 months post baseline
|
.Evaluate response in skin and blood using a modified skin weighted assessment tool that assess the tumor burden in the skin and blood flow cytometry that assesses the tumor burden in the blood.
If tumor burden detected internally (visceral) or in the lymph nodes at baseline, follow up CT scans will be used to evaluate lymph nodal and/or visceral response.
Response rate is defined as 50% or greater decrease in skin, lymph node/visceral, or blood tumor burden
|
Up to 3 months post baseline
|
Change from baseline in the objective response rate for ECP therapy
Time Frame: Up to 6 months post baseline
|
.Evaluate response in skin and blood using a modified skin weighted assessment tool that assess the tumor burden in the skin and blood flow cytometry that assesses the tumor burden in the blood.
If tumor burden detected internally (visceral) or in the lymph nodes at baseline, follow up CT scans will be used to evaluate lymph nodal and/or visceral response.
Response rate is defined as 50% or greater decrease in skin, lymph node/visceral, or blood tumor burden
|
Up to 6 months post baseline
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in the objective response rate by disease compartment
Time Frame: Up to 3 months post baseline
|
Evaluation of objective responses separated out by each subgroup of potential involvement (blood, skin, lymph nodes,and viscera (if present).
|
Up to 3 months post baseline
|
Change from baseline in the objective response rate by disease compartment
Time Frame: Up to 6 months post baseline
|
Evaluation of objective responses separated out by each subgroup of potential involvement (blood, skin, lymph nodes,and viscera (if present).
|
Up to 6 months post baseline
|
Correlation of clinical responses and changes in tumor microenvironment in the blood.
Time Frame: Up to 6 months post baseline
|
Technology using scRNAseq to analyze the blood microenvironment will be correlated with the clinical responses observed.
|
Up to 6 months post baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Oleg E Akilov, MD, PhD, University of Pittsburgh
Publications and helpful links
General Publications
- Ying Z, Shiue L, Park K, Kollet J, Bijani P, Goswami M, Duvic M, Ni X. Blood transcriptional profiling reveals IL-1 and integrin signaling pathways associated with clinical response to extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma. Oncotarget. 2019 May 7;10(34):3183-3197. doi: 10.18632/oncotarget.26900. eCollection 2019 May 7. Erratum In: Oncotarget. 2019 Sep 10;10(52):5492.
- Zic JA. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sezary Syndrome. Dermatol Clin. 2015 Oct;33(4):765-76. doi: 10.1016/j.det.2015.05.011. Epub 2015 Jul 29.
- Spary LK, Al-Taei S, Salimu J, Cook AD, Ager A, Watson HA, Clayton A, Staffurth J, Mason MD, Tabi Z. Enhancement of T cell responses as a result of synergy between lower doses of radiation and T cell stimulation. J Immunol. 2014 Apr 1;192(7):3101-10. doi: 10.4049/jimmunol.1302736. Epub 2014 Mar 5.
- Curion F, Handel AE, Attar M, Gallone G, Bowden R, Cader MZ, Clark MB. Targeted RNA sequencing enhances gene expression profiling of ultra-low input samples. RNA Biol. 2020 Dec;17(12):1741-1753. doi: 10.1080/15476286.2020.1777768. Epub 2020 Jun 28.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Disease
- Lymphoma
- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell
- Syndrome
- Sezary Syndrome
- Photosensitizing Agents
- Dermatologic Agents
- Methoxsalen
Other Study ID Numbers
- STUDY21100115
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sezary Syndrome
-
National Cancer Institute (NCI)Active, not recruitingMycosis Fungoides | Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8 | Recurrent Mycosis Fungoides... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMycosis Fungoides | Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage III Mycosis Fungoides... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Mycosis Fungoides and Sezary Syndrome | Refractory Mycosis Fungoides and Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIIA Mycosis... and other conditionsUnited States
-
Northwestern UniversityAmgenTerminatedRecurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma | Stage I Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IA Mycosis Fungoides/Sezary Syndrome | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Mycosis Fungoides and Sezary Syndrome | Refractory Mycosis Fungoides and Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIIA Mycosis... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...WithdrawnRecurrent Mycosis Fungoides and Sezary Syndrome | Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IIB Mycosis Fungoides and Sezary Syndrome | Stage IIIA Mycosis Fungoides and Sezary Syndrome | Stage IIIB Mycosis Fungoides and Sezary Syndrome | Stage IVA Mycosis Fungoides and Sezary Syndrome | Stage...
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingSezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Transformed Mycosis Fungoides | Folliculotropic... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingStage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8United States
-
Kevin Cooper MDNational Cancer Institute (NCI)CompletedRecurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Stage I Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IA Mycosis Fungoides/Sezary Syndrome | Stage IB Mycosis Fungoides/Sezary Syndrome | Stage II Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IIA Mycosis...United States
-
National Cancer Institute (NCI)TerminatedRecurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage III Mycosis Fungoides/Sezary Syndrome | Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IV Mycosis Fungoides/Sezary Syndrome | Stage I... and other conditionsUnited States
Clinical Trials on Extracorporeal photopheresis (ECP)
-
University of UtahIncyte CorporationTerminatedChronic Graft-versus-host-diseaseUnited States
-
Molly GalloglyNot yet recruitingGraft Versus Host DiseaseUnited States
-
Washington University School of MedicineThe Foundation for Barnes-Jewish Hospital; Mallinckrodt; Centers for Medicare...Active, not recruitingBronchiolitis Obliterans Syndrome (BOS)United States
-
Fondazione Policlinico Universitario Agostino Gemelli...Enrolling by invitationGraft Vs Host Disease | Extracorporeal PhotopheresisItaly
-
National Cancer Institute (NCI)TerminatedGraft vs Host Disease | Graft-Versus-Host Disease | Chronic Graft vs. Host DiseaseUnited States
-
Lawson Health Research InstituteMallinckrodtNot yet recruitingDiffuse Cutaneous Systemic SclerosisCanada
-
MallinckrodtICON plcCompletedCrohn's DiseaseBelgium, Germany, United States, Austria
-
Therakos, Inc., a Mallinckrodt CompanyTerminatedSteroid Refractory Acute Graft Versus Host DiseaseUnited States, Spain, France, Austria, Germany, Hungary, Italy, United Kingdom
-
Medical University of ViennaCompletedLung Transplant Rejection | Lung Transplant InfectionAustria
-
Fundación para la Investigación del Hospital Clínico...Completed